148 related articles for article (PubMed ID: 33854524)
21. STAT3-Induced Upregulation of lncRNA CASC9 Promotes the Progression of Bladder Cancer by Interacting with EZH2 and Affecting the Expression of PTEN.
Yuan B; Sun R; Du Y; Jia Z; Yao W; Yang J
Onco Targets Ther; 2020; 13():9147-9157. PubMed ID: 32982303
[TBL] [Abstract][Full Text] [Related]
22. MiR-27a promotes EMT in ovarian cancer through active Wnt/𝜷-catenin signalling by targeting FOXO1.
Zhang LY; Chen Y; Jia J; Zhu X; He Y; Wu LM
Cancer Biomark; 2019; 24(1):31-42. PubMed ID: 30614794
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway.
Xu H; Zhu J; Hu C; Song H; Li Y
J Physiol Biochem; 2016 Dec; 72(4):721-732. PubMed ID: 27534652
[TBL] [Abstract][Full Text] [Related]
25. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-544 promotes colorectal cancer progression by targeting forkhead box O1.
Yao GD; Zhang YF; Chen P; Ren XB
Oncol Lett; 2018 Jan; 15(1):991-997. PubMed ID: 29422969
[TBL] [Abstract][Full Text] [Related]
27. Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis.
Jia Q; Ye L; Xu S; Xiao H; Xu S; Shi Z; Li J; Chen Z
Thorac Cancer; 2020 Mar; 11(3):619-630. PubMed ID: 31962380
[TBL] [Abstract][Full Text] [Related]
28. MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells.
Janaki Ramaiah M; Lavanya A; Honarpisheh M; Zarea M; Bhadra U; Bhadra MP
Gene; 2014 Dec; 552(2):255-64. PubMed ID: 25261849
[TBL] [Abstract][Full Text] [Related]
29. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Huang JP; Ling K
Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
[TBL] [Abstract][Full Text] [Related]
30. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
31. Timeless-Stimulated miR-5188-FOXO1/β-Catenin-c-Jun Feedback Loop Promotes Stemness via Ubiquitination of β-Catenin in Breast Cancer.
Zou Y; Lin X; Bu J; Lin Z; Chen Y; Qiu Y; Mo H; Tang Y; Fang W; Wu Z
Mol Ther; 2020 Jan; 28(1):313-327. PubMed ID: 31604679
[TBL] [Abstract][Full Text] [Related]
32. MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing EZH2 Mediated miRNAs Dysregulated Expressions.
Shi Z; Li Y; Qian X; Hu Y; Liu J; Zhang S; Zhang J
J Cancer; 2017; 8(15):3037-3048. PubMed ID: 28928895
[TBL] [Abstract][Full Text] [Related]
33. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer.
Zhao XG; Hu JY; Tang J; Yi W; Zhang MY; Deng R; Mai SJ; Weng NQ; Wang RQ; Liu J; Zhang HZ; He JH; Wang HY
Cell Death Dis; 2019 Jun; 10(7):479. PubMed ID: 31209222
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
35. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
36. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
[TBL] [Abstract][Full Text] [Related]
38. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis.
Wang J; Shen L; Hong H; Li J; Wang H; Li X
Eur J Pharmacol; 2019 Jun; 852():142-150. PubMed ID: 30876973
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-409-3p regulates cell invasion and metastasis by targeting ZEB1 in breast cancer.
Ma Z; Li Y; Xu J; Ren Q; Yao J; Tian X
IUBMB Life; 2016 May; 68(5):394-402. PubMed ID: 27079864
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-137 is negatively associated with clinical outcome and regulates tumor development through EZH2 in cervical cancer.
Zhang H; Yan T; Liu Z; Wang J; Lu Y; Li D; Liang W
J Cell Biochem; 2018 Jan; 119(1):938-947. PubMed ID: 28681918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
